ADIA Nutrition Inc Appoints First Doctor of Its Medical Division
ADIA Nutrition Inc Appoints First Doctor of Its Medical Division
Winter Park, Florida--(Newsfile Corp. - August 20, 2024) - ADIA Nutrition Inc. (OTC Pink: ADIA) has appointed Dr. Monica Sher as one of the Directors of its Medical Division, where she will be instrumental in helping to establish the policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients.
佛羅里達州溫特公園——(新聞稿公司——2024年8月20日)——ADIA營養公司(OTC粉紅色:ADIA)任命莫妮卡·舍爾博士爲其醫療部門的董事之一,她將在幫助建立公司自體造血幹細胞移植(aHSCT)計劃爲多發性硬化症(MS)患者制定政策和程序方面發揮重要作用。
Dr. Monica Sher
莫妮卡·舍爾博士
Following a comprehensive search and selection process, Dr. Sher was chosen for her extensive experience and expertise in the field of medicine. With a background in Internal Medicine and a passion for health and wellness, she is well-suited to assist in leading ADIA Nutrition's efforts in advancing aHSCT therapies for MS.
在全面搜索和遴選的過程中,出於她在醫學領域的廣泛經驗和專業知識,選擇了舍爾博士。她具備內科背景和對健康和福利的熱愛,非常適合協助領導ADIA營養公司推進MS的aHSCT治療。
Dr. Sher expressed her excitement about joining ADIA Nutrition Inc., stating, "I am honored to become one of the directors of ADIA's Medical Division. This opportunity aligns perfectly with my passion for improving the lives of patients through stem cell therapy and cutting-edge medical interventions like aHSCT. I look forward to collaborating with the talented team at ADIA Nutrition to drive innovation and deliver exceptional care to our patients."
舍爾博士對加入ADIA營養公司感到興奮,表示:「我很榮幸能成爲ADIA醫療部門的一名主管。這次機會與我通過幹細胞療法和像aHSCT這樣的尖端醫學干預手段來改善患者生活的熱情完美契合。我期待着與ADIA營養公司的才華橫溢的團隊合作,推動創新,爲我們的患者提供卓越的護理。」
Larry Powalisz, CEO of ADIA Nutrition Inc., welcomed Dr. Sher to the team, saying, "We are thrilled to have Dr. Sher join us. Her knowledge and expertise in internal medicine and commitment to advancing Stem Cell treatment for MS through aHSCT will be invaluable as we continue to grow and expand our medical division. We are confident that Dr. Sher will be a great asset to our company and will aid ADIA in providing the highest level of care to our patients."
ADIA營養公司的首席執行官Larry Powalisz歡迎舍爾博士加入團隊,他說:「我們非常高興舍爾博士加入我們。她在內科領域的知識和專業知識,以及通過aHSCT推進MS幹細胞治療的承諾,將在我們繼續發展和擴展醫療部門方面發揮不可估量的價值。我們相信舍爾博士將是我們公司的一項重要資產,將幫助ADIA爲我們的患者提供最高水平的護理。」
In a unique arrangement, Dr. Sher has agreed to receive equity in the company in exchange for her directorial role, opting not to receive a salary. Instead, she will be compensated per each procedure, highlighting her dedication to the company's success and the advancement of medical treatment for MS.
在獨特的安排中,舍爾博士同意在交換她的主管角色時獲得公司的股權,選擇不接受薪水。相反,她將根據每個程序獲得報酬,突顯她對公司成功和推進MS醫療治療的奉獻精神。
For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
有關媒體查詢或更多信息,請通過ceo@adiamed.com或321-788-0850聯繫Larry Powalisz。
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division specializing in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments for Multiple Sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
關於ADIA營養公司:
Adia營養公司是一家公開交易公司(OTC Pink:ADIA),致力於改革醫療保健和補充劑。公司專注於創新和質量,已建立了兩個關鍵部門:提供高質量有機補充劑的補充部門和專門從事多發性硬化症(MS)的自體造血幹細胞移植(aHSCT)治療的醫療部門。通過這些部門,Adia營養公司致力於通過滿足營養需求和突破性的醫療治療措施來賦予個人更好的生活。
Website:
Website:
Website:
Website:
Twitter (X): @ADIA_Nutrition
網站:
網站:
網站:
網站:
Twitter(X):@ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
安全港:本新聞稿包含根據1933年證券法第27A條和1934年證券交易法第21E條的前瞻性聲明。這些前瞻性聲明基於管理層的當前計劃和期望,並受到一些不確定性和風險的影響,這些風險和不確定性可能會顯著影響公司的當前計劃和期望,以及未來的經營業績和財務狀況。關於公司業務前景以及可能影響公司業務前景並導致實際結果與前瞻性聲明描述的結果有很大不同的風險和因素的更詳細列表,可以在公司向證券交易委員會和OTC Markets,Inc. OTC Disclosure and News Service提交的報告和其他文件中找到。公司不承擔公開更新或修訂任何前瞻性聲明的義務,因爲有新信息,未來事件或其他情況。